We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




UTIs Diagnosed with Genetic Analysis of Cell-Free DNA

By LabMedica International staff writers
Posted on 03 Jul 2018
Genetic analysis of cell-free DNA (cfDNA) in urine samples reveals valuable information, which enables comprehensive monitoring of host and pathogen dynamics in bacterial and viral urinary tract infections.

Investigators at Cornell University (Ithaca, NY, USA) isolated cfDNA from 141 urine samples from a cohort of 82 kidney transplant recipients and performed next-generation sequencing.

The analysis revealed that urinary cfDNA was highly informative about bacterial and viral composition of the microbiome, antimicrobial susceptibility, bacterial growth dynamics, kidney allograft injury, and host response to infection. More...
These different layers of information were accessible from a single assay and individually agreed with corresponding clinical tests based on quantitative PCR, conventional bacterial culture, and urinalysis. Furthermore, cfDNA revealed the frequent occurrence of diseases that remained undiagnosed with conventional diagnostic protocols.

“We found that we could deduce the fraction of the bacterial population that is growing, by carefully looking at the places in the genome where the cell-free DNA was derived from” said senior author Dr. Iwijn De Vlaminck, professor of biomedical engineering at Cornell University. "Metagenomic analysis of the cell-free DNA can also be used to infer which antimicrobial drugs may work best against a particular infection."

The paper describing genetic analysis of cell-free DNA in urine specimens was published in the June 20, 2018, online edition of the journal Nature Communications.

Related Links:
Cornell University


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: The GenoPredict assay from Predicta Biosciences is available to Tempus Life Sciences partners to support exploratory research and clinical development programs (photo courtesy of Shutterstock)

Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring

Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.